Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Market Cap | $422 | $5,351 | $17,874 | $55,387 |
| - Cash | $83 | $12 | $492 | $327 |
| + Debt | $5,295 | $3,719 | $4,834 | $5,419 |
| Enterprise Value | $5,634 | $9,059 | $22,216 | $60,479 |
| Revenue | $5,261 | $7,112 | $9,556 | $7,296 |
| % Growth | -26% | -25.6% | 31% | – |
| Gross Profit | $3,165 | $4,896 | $6,566 | $4,095 |
| % Margin | 60.2% | 68.8% | 68.7% | 56.1% |
| EBITDA | -$1,663 | -$2,198 | -$3,429 | -$10,137 |
| % Margin | -31.6% | -30.9% | -35.9% | -138.9% |
| Net Income | -$3,044 | -$3,895 | -$9,338 | -$9,586 |
| % Margin | -57.9% | -54.8% | -97.7% | -131.4% |
| EPS Diluted | -0.11 | -0.15 | -0.39 | -0.43 |
| % Growth | 26.7% | 61.5% | 9.3% | – |
| Operating Cash Flow | -$1,279 | $780 | -$2,047 | -$2,373 |
| Capital Expenditures | -$0 | -$0 | -$121 | -$295 |
| Free Cash Flow | -$1,279 | $780 | -$2,168 | -$2,668 |